

7/25/2006

12810-00317-001
12810-00317-003
Docket No.: 12810-00317-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Andreas Habich et al.

Application No.: National Phase of
PCT/EP2005/000826

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: STABILIZED ENZYME FORMULATIONS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

10/587161


Application No.: National Phase of PCT/EP2005/000826

Docket No.: 12810-00317-US

AP20 Rec'd PCT/PTO 25 JUL 2006

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 12810-00317-US.

Respectfully submitted,

By 
Hui-Ju Wu

Registration No.: 57,209
CONNOLLY BOVE LODGE & HUTZ LLP
1007 North Orange Street
P.O. Box 2207
Wilmington, Delaware 19899
(302) 658-9141
(302) 658-5614 (Fax)
Agent for Applicants

476053

7/25/2006

2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	12810-00317-161
				Filing Date	Concurrently Herewith
				First Named Inventor	Andreas Habich
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	12810-00317-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/HRB/	AA*	US-5,141,755	08-25-1992	Weisman	
	AB*	US-5,318,903	06-07-1994	Bewert et al.	
	AC*	US-5,846,798	12-08-1998	Paatz et al.	
	AD*	US-6,475,546	11-05-2002	Harz et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
/HRB/	BA	WO-93/07260	04-15-1993	Genencor International, Inc.		
	BB	WO-01/58275	08-16-2001	F Hoffmann-La Roche AG		
	BC	WO-03/062409	07-31-2003	Roche Vitamins AG		
	BD	WO-95/06709	03-09-1995	Cognis Gesellschaft fur Bio- Und Umwelttechnologie MBH		
	BE	WO-00/36927	06-29-2000	BASF Aktiengesellschaft		See US 6,475,546
	BF	WO-03/059086	07-24-2003	DSM N.V.		
	BG	WO-03/059087	07-24-2003	DSM N.V.		
	BH	WO-97/16076	05-09-1997	Novo Nordisk A/S		
	BI	DE-1 958 104	05-19-1971	Knapsack AG		See GB 1 288 997
	BJ	DE-2 137 042	02-10-1972	Novo Terapeutisk Laboratorium A/S		See GB 1 362 365
	BK	DE-2 137 043	02-03-1972	Novo Terapeutisk Laboratorium A/S		See GB 1 361 387
	BL	EP-0 862 623	09-09-1998	Genencor International, Inc.		
	BM	EP-0 716 685	06-19-1996	Henkel Kommanditgesellschaft auf Aktien		See US 5,846,798
	BN	EP-0 758 018	02-12-1997	Gist-Brocades B.V.		
	BO	EP-1 069 832	01-24-2001	BASF Aktiengesellschaft		
	BP	GB-2 167 758	06-04-1986	Showa Denko Kabushiki Kaisha		
	BQ	GB-1 361 387	07-24-1974	Novo Terapeutisk Laboratorium A/S		
	BR	GB-1 362 365	08-07-1974	Novo Terapeutisk Laboratorium A/S		
	BS	GB-1 288 997	09-13-1972	Knapsack AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, ...)	
Examiner Signature	/Hamid Badr/	Date Considered	08/25/2009

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned 10/587161
				Filing Date	Concurrently Herewith
				First Named Inventor	Andreas Habich
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	12810-00317-US
Sheet	2	of	1		

Initials	No. ¹	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Hamid Badr/	Date Considered	08/25/2009
--------------------	--------------	-----------------	------------